Piramal Pharma Share Price Target Tomorrow From 2025 To 2030- Market Overview, Current Chart
Piramal Pharma is a trusted name in the healthcare and pharmaceutical world. The company provides high-quality medicines, health products, and specialized manufacturing services to people in India and around the world. Customers and partners feel satisfied with Piramal Pharma because of its focus on safety, innovation, and care. Piramal Pharma Share Price on NSE as of 16 June 2025 is 200.78 INR. This article will provide more details on Piramal Pharma Share Price Target 2025, 2026 to 2030.
Piramal Pharma Ltd: Company Info
- Founded: 2020
- Headquarters: India
- Number of employees: 6,719 (2024)
- Subsidiaries: Piramal Critical Care, Piramal Critical Care Limited.
Piramal Pharma Share Price Chart
Piramal Pharma Share: Market Overview
- Open: 197.00
- High: 201.70
- Low: 195.56
- Mkt cap: 26.51KCr
- P/E ratio: 295.26
- Div yield: N/A
- 52-wk high: 307.90
- 52-wk low: 145.25
Piramal Pharma Share Price Target Tomorrow From 2025 To 2030
Here are the estimated share prices of Piramal Pharma for the upcoming years, based solely on market valuation, enterprise trends and professional predictions.
- 2025 – ₹320
- 2026 – ₹370
- 2027 – ₹420
- 2028 – ₹470
- 2029 – ₹520
- 2030 – ₹570
Piramal Pharma Share Price Target 2025
Piramal Pharma share price target 2025 Expected target could be between ₹310 to ₹320. Here are 7 key factors that could shape the growth of Piramal Pharma share price by 2025:
1. Strong CDMO Momentum
Piramal’s CDMO (Contract Development & Manufacturing Organization) business, accounting for around 58% of FY24 revenue, is growing rapidly. Jefferies expects CDMO revenue and EBITDA to compound at ~12% and 20% respectively, driven by higher demand for specialized drug manufacturing.
2. Robust Order Book and Global Reach
Piramal holds a strong and steady flow of CDMO orders, particularly in new commercial molecules and generics like sevoflurane, which supports revenue visibility.
3. Favorable Macro Trends in Pharma Outsourcing
Global pharmaceutical companies are increasingly outsourcing to CDMOs, aided by “China‑Plus‑One” strategies, PLI incentives, and growing R&D trends—creating tailwinds for Piramal.
4. Solid Growth in Hospital Generics & OTC
The complex hospital generics division (e.g., critical care drugs) and the consumer healthcare business are gaining traction, with mid-teens CAGR expected in the OTC segment.
5. Analyst Upgrades & Price Target Revisions
Brokerages like ICICI, Jefferies, JM Financial, and Motilal Oswal have issued bullish calls, targeting ₹200–₹340 by mid‑2025, based on strong topline and margin recovery .
6. Earnings Growth & Margin Expansion
Jefferies forecasts a potential 55% upside by March 2025, with expectations of ~13% revenue CAGR and ~40% EBITDA CAGR. Improving margins will be driven by enhanced CDMO mix cnbctv18.com+1livemint.com+1.
7. Capacity Expansion Investments
Piramal is investing ~US$85–90 million (FY25) and doubling sterile fill-finish capacity (e.g., Lexington site), which will boost CDMO scale, efficiency, and earnings.
Piramal Pharma Share Price Target 2030
Piramal Pharma share price target 2030 Expected target could be between ₹560 to ₹570. Here are 7 key risks and challenges that could affect Piramal Pharma’s share price by 2030:
1. Regulatory Risks (USFDA & Global Compliance)
Piramal Pharma operates manufacturing facilities that are regularly inspected by global regulators like the USFDA. Any warning letters, import alerts, or quality issues could halt product approvals and damage reputation.
2. Overdependence on CDMO Business
A large portion of revenue comes from the CDMO (Contract Development and Manufacturing Organization) segment. Any slowdown in global outsourcing trends, client exits, or pricing pressure in this segment can significantly impact earnings.
3. Pricing Pressure in Generics & Hospital Business
Piramal’s complex generics business, especially in injectables and hospital generics, is exposed to intense pricing pressure from global competitors. This can reduce profit margins over time.
4. High Debt and Interest Burden
As of recent reports, the company has a relatively high debt level due to ongoing capital expenditure. Sustained high interest costs could weaken profitability if revenue growth doesn’t keep pace.
5. Execution Risks in Capacity Expansion
Ongoing investments in expanding manufacturing capacity—like doubling sterile fill-finish units—require timely execution. Delays, cost overruns, or underutilization could affect returns and share price performance.
6. R&D and Innovation Challenges
As the pharmaceutical industry evolves rapidly, failure to innovate or adapt to new drug delivery platforms, formulations, or client requirements could limit long-term competitiveness.
7. Client Concentration & Contract Dependency
Piramal’s CDMO business may depend heavily on a few large clients. If any key contract is canceled or not renewed, it can result in a sudden drop in revenue.
Shareholding Pattern For Piramal Pharma Share
| Held By | May 2025 |
| Promoters | 34.95% |
| Flls | 31.49% |
| Dlls | 14.78% |
| Public | 18.78% |
Piramal Pharma Financials
| (INR) | 2025 | Y/Y change |
| Revenue | 91.51B | 11.99% |
| Operating expense | 52.91B | 18.92% |
| Net income | 911.30M | 411.39% |
| Net profit margin | — | — |
| Earnings per share | 0.68 | 257.89% |
| EBITDA | 14.04B | 23.25% |
| Effective tax rate | 78.02% | — |
Read Also:- Jaiprakash Power Share Price Target Tomorrow From 2025 To 2030- Current Chart, Financials
